Ionis Pharmaceuticals, Inc. (IONS)

NMS – Цена в реальном времени. Валюта: USD

81.18

+2.84 (3.63%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

82.01

+0.83 (1.02%)

После закрытия: Jun 26, 2026, 7:36 PM EDT

10.06.2026

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.“We are pleased to welcome Dr. Hantson to the board,” said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. “Ludwig's biopharma executive leadership experience will be especially meaningful as Ionis prepares for a steady cadence of new c.

05.06.2026

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

05.06.2026

Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript

04.06.2026

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans (June 5-8), the National Lipid Association (NLA) Scientific Sessions in Ch.

29.05.2026

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

28.05.2026

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. IONS is transitioning from niche indications to multi-billion-dollar markets, leveraging key partnerships and upcoming product launches. Projected 2030 revenues exceed $5bn, driven by Tryngolza, Dawnzera, and significant royalty streams from eplontersen, bepiroversen, and pelacarsen.

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an.

14.05.2026

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease (AD). The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impac.

04.05.2026

Ionis to host 2026 virtual Annual Meeting of Stockholders

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2026, are invited to participate in the virtual Annual Meeting we.

Ionis Pharmaceuticals, Inc. (IONS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Видео

Пресс-релизы

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Видео

Пресс-релизы

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

Ionis to host 2026 virtual Annual Meeting of Stockholders

Search stocks

Ionis Pharmaceuticals, Inc. (IONS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Видео

Пресс-релизы

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Видео

Пресс-релизы

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

Ionis to host 2026 virtual Annual Meeting of Stockholders